PRODUCTS & SERVICES
In other news, after a seven-month hiatus precipitated by the coronavirus pandemic, we have officially resumed our EIC Accelerator project to validate Multiplex8+, our novel diagnostic test for breast cancer. To kick off this new beginning, we received our first batch of 300 archived FFPE breast cancer specimens from one of our biobank partners, PATH Biobank in Munich, Germany. We are so grateful to our colleagues at PATH and the patients who have provided consent to research organizations like us to use their specimens to identify novel biomarkers that can help save lives!
Over the next 16 months, we’ll be working hard on this project and to help us meet our goals and milestones we’ve hired six new scientists to join our team.
These talented young scientists have diverse backgrounds in fields spanning Molecular Biology, Genetics, Biochemistry, Data Science, and Chemical Engineering, they come from distinguished institutions around Europe, and have published in top tier journals including Nucleic Acids Research, Molecular Cell, and Current Biology. Join us in welcoming them aboard!
For a short overview of the workflow for our Multiplex8+ test see the schematic below. We’ll keep you updated in the coming months about our progress and interesting results.
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.